| 000 | 01706 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513162322.0 | ||
| 264 | 0 | _c19990305 | |
| 008 | 199903s 0 0 eng d | ||
| 022 | _a1073-449X | ||
| 024 | 7 |
_a10.1164/ajrccm.159.2.9805097 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSandman, L | |
| 245 | 0 | 0 |
_aRisk factors for rifampin-monoresistant tuberculosis: A case-control study. _h[electronic resource] |
| 260 |
_bAmerican journal of respiratory and critical care medicine _cFeb 1999 |
||
| 300 |
_a468-72 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xdiagnosis |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibiotics, Antitubercular _xtherapeutic use |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 | _aDrug Resistance, Microbial |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHIV _ximmunology |
| 650 | 0 | 4 |
_aHIV Seropositivity _xdiagnosis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLength of Stay |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMycobacterium tuberculosis _xdrug effects |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTuberculosis, Pulmonary _xdiagnosis |
| 700 | 1 | _aSchluger, N W | |
| 700 | 1 | _aDavidow, A L | |
| 700 | 1 | _aBonk, S | |
| 773 | 0 |
_tAmerican journal of respiratory and critical care medicine _gvol. 159 _gno. 2 _gp. 468-72 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1164/ajrccm.159.2.9805097 _zAvailable from publisher's website |
| 999 |
_c9889001 _d9889001 |
||